Ronald Moss

CMO at Adamis Pharmaceuticals Corporation. Prior to Adamis, Dr. Moss served as Chief Executive Officer of Ansun from October 2012 to February 2017. He previously served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine product development in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies. This has also included roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology.